- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02987036
Delivery of Beta Agonists is Technique Sensitive (DOBATS)Mechanics
Administration of Beta-agonistic Drug Using Two Different Nebulizer Technologies: Effects on Lung Mechanics
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The delivery of aerosols has a two fold appeal as it is distributed direct to the tracheo- bronchial tree and alveolar epithelium. The drug is then rapidly absorbed by the circulation avoiding the first pass entero-hepatic metabolic effect.
The systemic effects may be regarded as a side effect in the case were the primary therapeutic target is aimed at the bronchial tree as is the case with broncho-active drugs, such as β2-stimulants.
The ability of particles to remain suspended in a gas can be predicted from their size, shape and density, coupled with the density and viscosity of the gas. The properties of an aerosol is commonly expressed as the Mass Median Aerosol Diameter MMAD, a measure of the average particle size and the geometric standard deviation. It is calculated from the cumulative particle size curve1. The MMAD will give a reliable estimate of the likely deposition of the drug along the tracheo-bronchial tree. A particle size >5 will likely deposit in the upper airways, while particles with an MMAD of 2-5 is likely to deposit in the tracheo-bronchial tree2.
Jet nebulizers are the most commonly used devices for aerosol therapy. However, the MMAD generated by this device is unpredictable, often leading to the drug being deposited in the ventilator circuit or endotracheal tube3.
An alternative is the vibrating mesh nebulizer, which is based on a high frequency vibrating piezoelectric crystal. The crystal will vibrate a micron mesh at a very high frequency. A micro pump will deliver a small volume of liquid from a reservoir into the vibrating mesh resulting in a very precise aerosol generation3.
Nebulizer therapy is often prescribed without proven effects or proper evaluation of result. Indeed, two large multicenter trial in acute lung injury patients were discontinued at interim analyses due to lack of effect4,5. This lack of effect may be due to the nebulizer technology (Jet nebulizer), the indication (ARDS), or primary outcome.
The investigators would like to compare the difference in therapeutic effect between these two devices as this has not been published previously. It is well known that the physical properties of the generated aerosol may differ widely, depending on device and technology used. Hence, even if the same amount of drug is administered, distribution and uptake will not be the same. It can further be expected that the therapeutic response will be different.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Zhongda Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients on mechanical ventilation for more than 48 hours
- PEEPi ≥3 cm H2O and expected to remain on controlled mechanical ventilation for at least 24 hours.
Exclusion Criteria:
- Severe chronic lung disease with chronic hypercapnia (PCO2>45 mm Hg), Chronic hypoxemia (PO2< 55mm Hg with FiO2=0,21), hospitalization within last 6 months for respiratory failure (PCO2>50; PO2<55mm Hg), Secondary polycythemia, severe pulmonary hypertension (mPAP >40 mm Hg.
- Unable to obtain consent
- Acute myocardial infarction
- Severe congestive heart failure
- Heart rate greater than maximal predicted heart rate MHR85 (MHR 85=0.85 x (220-age).
- Burns over more than 40% of body surface area
- Cancer or other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%
- Allogenic bone marrow transplantation within 5 years prior to the study
- Diffuse alveolar hemorrhage from vaculitis
- Morbid obesity
- Moribund, not expected to survive 24 hours
- Daily use of beta agonists prior to hospitalization
- Participation in other study
- Chronic liver disease
- Neuromuscular disease that impairs ability to breath without assistance (e.g. Cervical spine cord injury at level C5 and higher, Amyotrophic lateral sclerosis, Guillain-Barre syndrome or myasthenia gravis)
- Pregnant or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aerogen
Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
|
Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
|
Other: Jet Nebulizer
Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
|
Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change of intrinsi PPPE
Time Frame: 0, 5min, 60min, 6h after the first administration; 5min, 60 min and 18 h after second administration
|
0, 5min, 60min, 6h after the first administration; 5min, 60 min and 18 h after second administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change of respioratory resistance
Time Frame: 0, 5min, 60min, 6h after the first administration; 5min, 60 min and 18 h after second administration
|
0, 5min, 60min, 6h after the first administration; 5min, 60 min and 18 h after second administration
|
change of respiratory system Compliance
Time Frame: 0, 5min, 60min, 6h after the first administration; 5min, 60 min and 18 h after second administration
|
0, 5min, 60min, 6h after the first administration; 5min, 60 min and 18 h after second administration
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ling Ling, Dr, Zhongda Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- nebulizer
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
Poitiers University HospitalRecruitingAcute Respiratory Failure | Hypoxemic Respiratory FailureFrance
-
Catholic University of the Sacred HeartFisher and Paykel HealthcareCompletedWeaning Failure | Acute Respiratory FailureFrance, Greece, Italy, Spain
-
Hemovent GmbHMAXIS Medical, LLCActive, not recruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory FailureGermany
-
Hospital Clinic of BarcelonaCompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory FailureSpain
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
Efficacy Care R&D LtdMemorial Hermann Hospital; CRG Medical, Inc.UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest | Acute Respiratory Failure With Hypoxia | Acute Respiratory Failure Requiring Reintubation | Acute... and other conditionsUnited States
-
Siriraj HospitalRecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureThailand
-
Fisher and Paykel HealthcareCentre hospitalier de l'Université de Montréal (CHUM); Institut universitaire...Not yet recruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
University Hospital, AngersNot yet recruitingCardio-Respiratory FailureFrance
-
University Hospital, MotolCompletedRefractory Respiratory FailureCzechia
Clinical Trials on Aerogen
-
Sultan Abdulhamid Han Training and Research Hospital...Recruiting
-
University of SaskatchewanCompleted
-
McMaster UniversityUnknown
-
University of SaskatchewanCompleted
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Carmel Medical CenterCompletedLaparoscopic Surgical ProceduresIsrael
-
Chelsea and Westminster NHS Foundation TrustCompleted
-
Rush University Medical CenterCompletedRespiratory InsufficiencyUnited States
-
Hospital Universitari Joan XXIII de Tarragona.TerminatedVentilator Associated Pneumonia | Prevention | Respiratory Infection OtherSpain
-
Cliniques universitaires Saint-Luc- Université...CompletedBrain Injuries, TraumaticBelgium